

AREVIR-GenaFor-Meeting
Verbundprojekt Monitoring von resistenten HIV bei frisch infizierten und
chronisch infizierten HIV-Patienten in Deutschland
EuResist

When: 05.05. – 06. 05. 2011 (9:00 am – 18:30 pm)

Where: Stiftung caesar, Ludwig Erhard Allee 2, 53175 Bonn

Contact: Claudia.Mueller@med.uni-duesseldorf.de for registration and accommodation

Resistance testing is meanwhile „standard of care“ Different projects such as AREVIR, the „Verbundprojekt Monitoring von resistenten HIV mit RESINA und der RKI Serokonverter-Analyse“ contribute to better interpretation systems and analyze the risk of transmission of resistant HIV in Germany. The successful disciplinary work between clinicians, virologists and bioinformaticians started in 1999 and was honoured with the Heinz Ansmann Price 2010 for Thomas Lengauer, Mark Oette and Rolf Kaiser. On a European level the results of AREVIR and RESINA are integrated into the EUResist project together with the Karolinska and ARCA data and recently other European partners (www.euresist.org). Our aim is the prediction of the most likely best working drug combinations. For that reason, geno2pheno-THEO (www.genafor.org) was developed and meanwhile integrated into the EUResist prediction tool which is also freely available via internet. Nevertheless we need to understand the contribution of each resistance associated mutation and we have to agree on strategies for resistance testing and interpretation. These are the aims of HIV-GRADE (www.hiv-grade.de).

New drugs in new classes require equivalent diagnostics. Within HIV-GRADE and geno2pheno such new interpretation tools have been developed. This includes the prediction of the co receptor usage prior to therapy with co receptor blockers like maraviroc and resistance to integrase inhibitors like raltegravir.

For HBV the technical expertise from the HIV-projects could be adapted, so that interpretation systems are already available. Geno2pheno and HIV-GRADE predict resistance, (sub-) genotype and escape mutants. In the near future we will have to deal with resistance to anti-HCV drugs therefore an need appropriate tool was developed.

Since 2000 the meeting is an exchange platform for clinicians, bioinformaticians and virologists. Participants have the chance to discuss clinical cases with other experts – the fasta file of the relevant case from HIV or HBV and clinical information is needed, while the interpretation systems can be utilized online at the meeting. The suppliers of the commercial systems will also be present. Furthermore, protocols are available at the meeting and will be visible on the internet after the meeting under www.genafor.org.

The language of the meeting is English.

Friday, 06.05.2011

9:00 – 10:00

Databases and projects

Chairs:

Mark Oette, Eugen Schülter

**ESAR (Eu-Network)
RKI-CLINSERV/seroconverter study
Data from the RESINA cohort
Kompetenznetz**

Speakers:

Annemarie Wensing, Claudia Kücherer, Barbara Bartmeyer, Stefan Reuter, Klaus Jansen (angefragt)

10:00 – 12:00

Workshop

Protocols, interpretation, clinical application

1.) Coreceptor

Martin Obermeier, Alexander Thielen, Ramona Pauli

2.) HBV

Andreas Erhardt, Jens Verheyen, Bastian Beggel

3.) HCV

Saleta Sierra-Aragon, Christoph Boesecke,
Sven Eric Schelhorn

12:00 – 12:30

Summary workshops

12:30 – 13:30

New sequencing technologies replacing Sanger seq?

Chairs:

Hauke Walter, Alexander Thielen

Speaker:

Martin Däumer

13:30 – 14:30

Lunch

14:30 – 18:00

EuResist present and future:

Chairs:

Maurizio Zazzi, Francesca Incardona

Bioinformatics perspectives

Speaker:

Thomas Lengauer

**Therapy-Naïve-Tools
Prediction based on therapy history
HIV - Infcare
HIV resistance, treatment perspectives and data collection in
Russia, Tanzania, Vietnam, Kenya, Ethiopia, India**

Speakers:

Alejandro Pironti, Mattia Prosperi, Andres Sonnerborg, Dmitry Kuevda (Russia), Mloka (Tanzania), Kyong (Vietnam), Mwau (Kenya), Wondwosen (Ethiopia), Kumarasamy (India)

18:00

Summary

Rolf Kaiser

The Meeting is kindly supported by:

ViiV Healthcare, Abbott, Roche, Boehringer Ingelheim, Janssen, Bristol-Myers Squibb, Gilead, Siemens, MSD Sharp & Dohme, Qiagen

The meeting is certified from the Ärztekammer Nordrhein.

The Meeting is organised by genafor e.V.

Organising committee:

Daniel Hoffmann, Thomas Lengauer, Francesca Incardona, Maurizio Zazzi, Stefan Reuter, Jens Verheyen, Rolf Kaiser, Mark Oette and Claudia Müller

